• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves' Orbitopathy.

作者信息

George Augustine, Diana Tanja, Längericht Jan, Kahaly George J

机构信息

Molecular Thyroid Research Laboratory, Department of Medicine I, Johannes Gutenberg University (JGU) Medical Center, Mainz, Germany.

出版信息

Front Endocrinol (Lausanne). 2021 Feb 2;11:629925. doi: 10.3389/fendo.2020.629925. eCollection 2020.

DOI:10.3389/fendo.2020.629925
PMID:33603715
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7885640/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c958/7885640/48b58be6be23/fendo-11-629925-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c958/7885640/48b58be6be23/fendo-11-629925-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c958/7885640/48b58be6be23/fendo-11-629925-g001.jpg

相似文献

1
Stimulatory Thyrotropin Receptor Antibodies Are a Biomarker for Graves' Orbitopathy.刺激性促甲状腺素受体抗体是格雷夫斯眼病的生物标志物。
Front Endocrinol (Lausanne). 2021 Feb 2;11:629925. doi: 10.3389/fendo.2020.629925. eCollection 2020.
2
Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.格雷夫斯眼眶病慢性非活动期促甲状腺激素受体抗体水平与疾病严重程度的临床关联
Korean J Ophthalmol. 2015 Aug;29(4):213-9. doi: 10.3341/kjo.2015.29.4.213. Epub 2015 Jul 21.
3
Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy.血清抗促甲状腺激素受体自身抗体（TRAbs）与格雷夫斯眼病临床特征的相关性。
J Endocrinol Invest. 2021 Mar;44(3):581-585. doi: 10.1007/s40618-020-01353-y. Epub 2020 Jul 9.
4
Correlation between TSH receptor antibody assays and clinical manifestations of Graves' orbitopathy.促甲状腺激素受体抗体检测与 Graves 眼病临床表现的相关性。
Yonsei Med J. 2013 Jul;54(4):1033-9. doi: 10.3349/ymj.2013.54.4.1033.
5
Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease.格雷夫斯病患儿促甲状腺素刺激抗体和促甲状腺素结合抑制性免疫球蛋白检测
Endocr J. 2005 Oct;52(5):505-10. doi: 10.1507/endocrj.52.505.
6
Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.促甲状腺素受体抗体与Graves眼病临床特征的关联
Clin Endocrinol (Oxf). 2000 Mar;52(3):267-71. doi: 10.1046/j.1365-2265.2000.00959.x.
7
Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.格雷夫斯病和格雷夫斯眼病患者血清中胰岛素样生长因子-1 受体（IGF-1R）抗体。
J Endocrinol Invest. 2019 Apr;42(4):471-480. doi: 10.1007/s40618-018-0943-8. Epub 2018 Aug 21.
8
High Titers of Thyrotropin Receptor Antibodies Are Associated With Orbitopathy in Patients With Graves Disease.促甲状腺激素受体抗体滴度高与 Graves 病患者的眼病有关。
J Clin Endocrinol Metab. 2019 Jul 1;104(7):2561-2568. doi: 10.1210/jc.2018-02705.
9
IgG4 serum levels in Graves' orbitopathy.Graves 眼病患者的 IgG4 血清水平。
J Endocrinol Invest. 2024 Jul;47(7):1711-1717. doi: 10.1007/s40618-023-02265-3. Epub 2023 Dec 21.
10
Thyrotropin receptor antibodies and Graves' orbitopathy.促甲状腺素受体抗体与格雷夫斯眼病。
J Endocrinol Invest. 2021 Apr;44(4):703-712. doi: 10.1007/s40618-020-01380-9. Epub 2020 Aug 4.

引用本文的文献

1
Expression, immunogenicity and clinical significance analysis of thyroid‑stimulating hormone receptor fusion proteins.促甲状腺激素受体融合蛋白的表达、免疫原性及临床意义分析
Mol Med Rep. 2025 Oct;32(4). doi: 10.3892/mmr.2025.13639. Epub 2025 Aug 1.
2
The burden of illness in thyroid eye disease: current state of the evidence.甲状腺眼病的疾病负担：证据现状
Front Ophthalmol (Lausanne). 2025 Apr 17;5:1565762. doi: 10.3389/fopht.2025.1565762. eCollection 2025.
3
The role of IL-6 in thyroid eye disease: an update on emerging treatments.

本文引用的文献

1
A Novel Long-Term Graves' Disease Animal Model Confirmed by Functional Thyrotropin Receptor Antibodies.一种由功能性促甲状腺激素受体抗体证实的新型长期格雷夫斯病动物模型。
Eur Thyroid J. 2020 Dec;9(Suppl 1):51-58. doi: 10.1159/000508790. Epub 2020 Jul 23.
2
Management of Graves Thyroidal and Extrathyroidal Disease: An Update.格雷夫斯甲状腺和甲状腺外疾病的管理：更新。
J Clin Endocrinol Metab. 2020 Dec 1;105(12):3704-20. doi: 10.1210/clinem/dgaa646.
3
Thyrotropin receptor antibodies and Graves' orbitopathy.促甲状腺素受体抗体与格雷夫斯眼病。
白细胞介素-6在甲状腺眼病中的作用：新兴治疗方法的最新进展
Front Ophthalmol (Lausanne). 2025 Apr 14;5:1544436. doi: 10.3389/fopht.2025.1544436. eCollection 2025.
4
Analytical validation of a novel bioassay for thyroid-stimulating immunoglobulin.一种新型促甲状腺素免疫球蛋白生物测定法的分析验证
Front Endocrinol (Lausanne). 2025 Jan 7;15:1468768. doi: 10.3389/fendo.2024.1468768. eCollection 2024.
5
Mechanisms in Thyroid Eye Disease: The TSH Receptor Interacts Directly With the IGF-1 Receptor.甲状腺眼病的发病机制：促甲状腺激素受体与胰岛素样生长因子-1受体直接相互作用。
Endocrinology. 2025 Jan 6;166(2). doi: 10.1210/endocr/bqaf009.
6
Evaluation of corticoresistance in patients with thyroid eye disease and use of rituximab as a second-line treatment.甲状腺眼病患者皮质激素抵抗的评估及利妥昔单抗作为二线治疗的应用。
Endocrine. 2025 Mar;87(3):1112-1119. doi: 10.1007/s12020-024-04108-4. Epub 2024 Nov 28.
7
Advances of IGF-1R inhibitors in Graves' ophthalmopathy.IGF-1R 抑制剂在 Graves 眼病中的研究进展。
Int Ophthalmol. 2024 Nov 22;44(1):435. doi: 10.1007/s10792-024-03358-5.
8
The TSH Receptor Antibody Reactome Contributes to Retro-Orbital Inflammation.促甲状腺激素受体抗体反应组与眶后炎症有关。
J Endocr Soc. 2024 Oct 22;8(12):bvae182. doi: 10.1210/jendso/bvae182. eCollection 2024 Oct 29.
9
Clinical performance of a novel and rapid bioassay for detection of thyroid-stimulating immunoglobulins in Graves' orbitopathy patients: a comparison with two commonly used immunoassays.新型快速生物测定法检测 Graves 眼病患者甲状腺刺激免疫球蛋白的临床性能：与两种常用免疫测定法的比较。
Front Endocrinol (Lausanne). 2024 Sep 27;15:1469179. doi: 10.3389/fendo.2024.1469179. eCollection 2024.
10
Prognostic factors for thyroid-stimulating immunoglobulin normalization in moderate-to-severe Graves' orbitopathy: a 36-month longitudinal study.中重度 Graves 眼病甲状腺刺激免疫球蛋白正常化的预后因素：一项 36 个月的纵向研究。
BMC Ophthalmol. 2024 Aug 21;24(1):361. doi: 10.1186/s12886-024-03594-4.
J Endocrinol Invest. 2021 Apr;44(4):703-712. doi: 10.1007/s40618-020-01380-9. Epub 2020 Aug 4.
4
Graves' disease.格雷夫斯病。
Nat Rev Dis Primers. 2020 Jul 2;6(1):52. doi: 10.1038/s41572-020-0184-y.
5
TSH RECEPTOR ANTIBODIES: RELEVANCE & UTILITY.促甲状腺激素受体抗体：意义与应用。
Endocr Pract. 2020 Jan;26(1):97-106. doi: 10.4158/EP-2019-0363.
6
Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease.格雷夫斯病中功能性促甲状腺素受体抗体的前瞻性试验
J Clin Endocrinol Metab. 2020 Apr 1;105(4):e1006-14. doi: 10.1210/clinem/dgz292.
7
Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis.模仿格雷夫斯眼病的眼眶疾病：鉴别诊断中的长期挑战。
J Endocrinol Invest. 2020 Apr;43(4):401-411. doi: 10.1007/s40618-019-01141-3. Epub 2019 Nov 5.
8
Immunohistochemical analysis of human orbital tissue in Graves' orbitopathy.Graves 眼病患者眼眶组织的免疫组化分析。
J Endocrinol Invest. 2020 Feb;43(2):123-137. doi: 10.1007/s40618-019-01116-4. Epub 2019 Sep 19.
9
Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody Detection and Differentiation.桥联免疫分析法与两种生物分析法检测和区分促甲状腺素受体抗体的比较。
Horm Metab Res. 2019 Jun;51(6):341-346. doi: 10.1055/a-0914-0535. Epub 2019 Jun 17.
10
High Titers of Thyrotropin Receptor Antibodies Are Associated With Orbitopathy in Patients With Graves Disease.促甲状腺激素受体抗体滴度高与 Graves 病患者的眼病有关。
J Clin Endocrinol Metab. 2019 Jul 1;104(7):2561-2568. doi: 10.1210/jc.2018-02705.